-
EP4000619
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP4000619
| EP4000619 - DOSAGE REGIMEN FOR AN ALPHA-ISOFORM SELECTIVE PHOSPHATIDYLINOSITOL 3-KINASE INHIBITOR [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 28.04.2023 Database last updated on 09.04.2026 | |
| Former | The application has been published Status updated on 22.04.2022 | Most recent event Tooltip | 28.04.2023 | Application deemed to be withdrawn | published on 31.05.2023 [2023/22] | Applicant(s) | For all designated states Novartis AG Lichtstrasse 35 4056 Basel / CH | [2022/21] | Inventor(s) | 01 /
Di Tomaso, Emmanuelle Lexington, 02420 / US | 02 /
Fritsch, Christine 4002 Basel / CH | 03 /
Germa, Marie-Caroline Short Hills, 07936 / US | 04 /
Massacesi, Cristian 92200 Neuilly Sur-Seine / FR | 05 /
Schnell, Christian René 4002 Basel / CH | 06 /
Tavorath, Ranjana Basking Ridge, 07920 / US | [2022/21] | Representative(s) | Rudge, Sewkian Novartis Pharma AG Patent Department 4002 Basel / CH | [2022/21] | Application number, filing date | 21193406.2 | 03.12.2014 | [2022/21] | Priority number, date | EP20130306679 | 06.12.2013 Original published format: EP 13306679 | [2022/21] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | EP4000619 | Date: | 25.05.2022 | Language: | EN | [2022/21] | Search report(s) | (Supplementary) European search report - dispatched on: | EP | 25.03.2022 | Classification | IPC: | A61K31/4439, A61P35/00 | [2022/21] | CPC: |
A61K31/4439 (EP,IL,KR,RU,US);
A61K31/427 (IL,KR);
A61K45/06 (IL,KR);
A61K9/0053 (IL,US);
A61P35/00 (EP,IL,RU);
A61K2300/00 (IL,KR)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2022/21] | Extension states | BA | Not yet paid | ME | Not yet paid | Title | German: | DOSIERUNGSSCHEMA FÜR EINEN ALPHA-ISOFORM-SELEKTIVEN PHOSPHATIDYLINOSITOL-3-KINASE-HEMMER | [2022/21] | English: | DOSAGE REGIMEN FOR AN ALPHA-ISOFORM SELECTIVE PHOSPHATIDYLINOSITOL 3-KINASE INHIBITOR | [2022/21] | French: | SCHÉMA POSOLOGIQUE D'UN INHIBITEUR DE LA PHOSPHATIDYLINOSITOL 3-KINASE SÉLECTIF DE L'ISOFORME ALPHA | [2022/21] | Examination procedure | 26.11.2022 | Application deemed to be withdrawn, date of legal effect [2023/22] | 13.01.2023 | Despatch of communication that the application is deemed to be withdrawn, reason: examination fee not paid in time [2023/22] | Parent application(s) Tooltip | EP14812658.4 / EP3076969 | Fees paid | Renewal fee | 03.01.2022 | Renewal fee patent year 03 | 03.01.2022 | Renewal fee patent year 04 | 03.01.2022 | Renewal fee patent year 05 | 03.01.2022 | Renewal fee patent year 06 | 03.01.2022 | Renewal fee patent year 07 | 30.11.2021 | Renewal fee patent year 08 | Penalty fee | Additional fee for renewal fee | 31.12.2022 | 09 M06 Not yet paid |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [YD] WO2010029082 (NOVARTIS AG et al.) | [Y] WO2012062694 (NOVARTIS AG et al.) | [YD] A M GONZALEZ-ANGULO: "Safety, pharmacokinetics, and preliminary activity of the [alpha]-specific PI3K inhibitor BYL719: Results from the first-in-human study.", 31 May 2013 (2013-05-31), XP055114130, Retrieved from the Internet | [A] FURET PASCAL ET AL: "Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, AMSTERDAM, NL, vol. 23, no. 13, 14 May 2013 (2013-05-14), pages 3741 - 3748, XP028564917, ISSN: 0960-894X, DOI: 10.1016/J.BMCL.2013.05.007 DOI: http://dx.doi.org/10.1016/j.bmcl.2013.05.007 | by applicant | WO2010029082 | US5457105 | US5616582 | US5770599 | WO0132651 | US5747498 | WO9630347 | US6727256 | WO0202552 | WO0160814 | US5883113 | WO9961422 | US6605617 | US6774237 | US6258812 | WO02057423 | WO9606116 | US4323581 | WO02062826 | WO9410202 | US5621100 | WO2004009769 | WO0100245 | WO9517182 | US2003171303 | WO03082272 | WO9720842 | WO9902162 | US2003134846 | WO9721701 | US5780454 | US4169846 | WO03024978 | WO03004505 | US5041424 | US5478932 | WO0230941 | WO9707081 | WO8907105 | WO9307153 | WO0104125 | WO9308809 | WO9406799 | WO0027422 | WO9613506 | WO8807045 | WO0179255 | WO9804541 | US6025387 | WO2004006834 | US6331555 | US4689338 | US5389640 | US5268376 | US4929624 | US5266575 | US5352784 | US5494916 | US5482936 | US5346905 | US5395937 | US5238944 | US5525612 | WO2004087153 | WO2004064759 | WO2004060308 | WO9512660 | WO9405304 | WO9729780 | WO9805769 | WO9843095 | VANHAESEBROECK ET AL., ANNU. REV. BIOCHEM, vol. 70, 2001, pages 535 | KATSO ET AL., ANNU. REV. CELL DEV. BIOL., vol. 17, 2001, pages 615 - 675 | FRUMAN ET AL., ANNU REV. BIOCHEM., vol. 67, 1998, pages 481 | SUIRE ET AL., CURR. BIOL., vol. 15, 2005, pages 566 | STEPHENS ET AL., CELL, vol. 89, 1997, pages 105 | CANTLEY ET AL., CELL, vol. 64, 1991, pages 281 | ESCOBEDOWILLIAMS, NATURE, vol. 335, 1988, pages 85 | FANTL ET AL., CELL, vol. 69, 1992, pages 413 | SAMUELS ET AL., CELL CYCLE, vol. 3, no. 10, 2004, pages 1221 | HARTMANN ET AL., ACTA NEUROPATHOL., vol. 109, no. 6, June 2005 (2005-06-01), pages 639 | LI ET AL., BMC CANCER, vol. 5, no. 29, March 2005 (2005-03-01) | LEE ET AL., ONCOGENE, vol. 24, no. 8, 2005, pages 1477 | BACKMAN ET AL., CANCER BIOL. THER., vol. 3, no. 8, 2004, pages 772 - 775 | CAMPBELL ET AL., CANCER RESEARCH, vol. 64, no. 21, 2004, pages 7678 - 7681 | LEVINE ET AL., CLIN. CANCER RES., vol. 11, no. 8, 2005, pages 2875 - 2878 | WU ET AL., BREAST CANCER RES., vol. 7, no. 5, 2005, pages R609 - R616 | PARSONS ET AL., NATURE, vol. 436, no. 792, 2005 | HENNESSEY AT EL., NATURE REV. DRUG DISC., vol. 4, 2005, pages 988 - 1004 | GONZALEZ-ANGULO ET AL.: "Safety, pharmacokinetics, and preliminary activity of the a-specific PI3K inhibitor BYL719: results from the first-in-human study", PRESENTATION AT THE 2013 ASCO ANNUAL MEETING, HELD, 2013 | TETRAHEDRON LETT., vol. 26, 1974, pages 2269 - 70 | HOLFORD, N. H. G.SCHEINER, L. B., CLIN. PHARMACOKINET, vol. 6, 1981, pages 429 - 453 | LOEWE, S.MUISCHNEK, H., ARCH. EXP. PATHOL PHARMACOL., vol. 114, 1926, pages 313 - 326 | CHOU, T. C.TALALAY, P., ADV. ENZYME REGUL., vol. 22, 1984, pages 27 - 55 | MAIRA ET AL., MOLECULAR CANCER THERAPEUTICS, vol. 11, 2012, pages 317 - 328 |